Expert Interview
Discussing Chimerix’ ONC206 Candidate in Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors
Ticker(s): CMRXAn oncologist with experience in treating Recurrent Diffuse Midline Gliomas and Other Recurrent Malignant Brain Tumors.
Please tell us about your clinical experience. How many patients with primary central nervous system tumors do you see on a yearly basis? What is the standard of care in newly diagnosed or recurrent Diffuse Midline Gliomas?
Added By: slingshot_insightsWhat can you tell us about the drug from how the trial design is structured?
How important do you see the pathway of the drug to be, of activating the integrated stress response and inhibition of Ras signaling, leading to selective killing of tumor cells? What are the important endpoints the drug should address?
How much of an unmet need is there in newly diagnosed or recurrent DIPG?
Can you tell us more about the mechanism of action of ONC206, as a DRD2 antagonist and ClpP agonist with nanomolar potency?
Could you make a parallel to Stanford’s CAR-T targeting disialoganglioside GD2 glycolipid? Can you comment on the data available so far?
How likely would you be to prescribe ONC206 in the future, what’s its potential to become a widely used drug in treating Diffuse Midline Gliomas?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
